Doptelet (Avatrombopag Maleate) Patent Expiration, LOE Window & CMS Spending

Doptelet (Avatrombopag Maleate) by Akarx: FDA Orange Book core substance LOE 2027-07-28 (last listed 2032-07-24), 0 AB generics, $196.1M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAkarx
FDA Application & PathwayN210238 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2027-07-28
Last Listed Patent or Exclusivity Date2032-07-24
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$196.1M
2024 Medicare Part D Spend$159.7M
2024 Medicaid Spend$36.4M
Reported Wholesale Price Change (CA SB 17)6 WAC filings (max 20.1% 2-yr change)